General
RegeneRx Biopharmaceuticals, Inc. (the Company, We, Us, Our), is a biopharmaceutical company focused on the discovery and development of novel molecules to accelerate
tissue and organ repair. Currently, we are developing Thymosin beta 4 (Tß4 ), a 43 amino acid
peptide. Current research suggests that Tß4 may prove efficacious for multiple medical indications, therefore we are developing several Tß4-based therapeutic products. We hold over fifty world-wide patents and patent applications
related to dermal, ophthalmic, and internal wounds and tissue repair, cardiac and neurological...
Research Report
Hotstocked.com has a complete research report available for RGN stock.
Download RGN report.
Research Report
Get the full report for FREE
| Date: | Sep 4, 2008 |
|---|---|
| Price: | Free |
| Pages: | 5 |
| Document Type: | Adobe Acrobat Reader |
| Download RGN report | |
| Example preview: |
|




